Wellington Management Group LLP Has $42.46 Million Stock Holdings in Artivion, Inc. $AORT

Key Points

• Wellington Management Group LLP increased its stake in Artivion by 4.1%, owning approximately 4.05% of shares valued at $42.46 million as of the first quarter.
• Artivion reported $0.24 earnings per share for the recent quarter, significantly exceeding analysts' expectations of $0.11, and its revenue increased by 15.3% year-over-year.
• Analysts have mixed outlooks on Artivion, with several raising price targets, resulting in an average target of $40.63 and a consensus rating of "Buy".

Wellington Management Group LLP boosted its stake in Artivion, Inc. (NYSE:AORT - Free Report) by 4.1% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,727,408 shares of the company's stock after acquiring an additional 67,327 shares during the quarter. Wellington Management Group LLP owned 4.05% of Artivion worth $42,460,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Millennium Management LLC increased its stake in Artivion by 25.1% in the 4th quarter. Millennium Management LLC now owns 165,482 shares of the company's stock valued at $4,731,000 after buying an additional 33,220 shares during the last quarter. Illinois Municipal Retirement Fund increased its stake in Artivion by 3.1% in the 1st quarter. Illinois Municipal Retirement Fund now owns 20,519 shares of the company's stock valued at $504,000 after buying an additional 611 shares during the last quarter. Principal Financial Group Inc. increased its stake in Artivion by 2.4% in the 1st quarter. Principal Financial Group Inc. now owns 206,777 shares of the company's stock valued at $5,083,000 after buying an additional 4,749 shares during the last quarter. Deutsche Bank AG increased its stake in Artivion by 45.1% in the 4th quarter. Deutsche Bank AG now owns 36,982 shares of the company's stock valued at $1,057,000 after buying an additional 11,501 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Artivion by 3.3% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,559 shares of the company's stock valued at $645,000 after buying an additional 727 shares during the last quarter. 86.37% of the stock is currently owned by institutional investors and hedge funds.

Artivion Price Performance

NYSE:AORT traded up $0.25 on Thursday, hitting $43.99. The company had a trading volume of 274,009 shares, compared to its average volume of 444,878. The stock has a market capitalization of $2.08 billion, a price-to-earnings ratio of -104.76 and a beta of 1.64. The company has a current ratio of 4.78, a quick ratio of 3.48 and a debt-to-equity ratio of 0.52. The firm has a 50 day moving average of $34.51 and a two-hundred day moving average of $29.13. Artivion, Inc. has a 52 week low of $21.97 and a 52 week high of $45.07.

Artivion (NYSE:AORT - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.24 EPS for the quarter, beating the consensus estimate of $0.11 by $0.13. The business had revenue of $112.97 million during the quarter, compared to the consensus estimate of $107.96 million. Artivion had a negative net margin of 4.43% and a positive return on equity of 5.70%. The company's revenue was up 15.3% on a year-over-year basis. Artivion has set its FY 2025 guidance at EPS. On average, research analysts anticipate that Artivion, Inc. will post 0.37 earnings per share for the current year.

Insider Buying and Selling at Artivion

In other Artivion news, SVP Marshall S. Stanton sold 26,132 shares of the company's stock in a transaction that occurred on Friday, June 13th. The shares were sold at an average price of $28.44, for a total value of $743,194.08. Following the completion of the transaction, the senior vice president directly owned 79,200 shares in the company, valued at approximately $2,252,448. This represents a 24.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Jean F. Holloway sold 23,356 shares of the company's stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $43.01, for a total transaction of $1,004,541.56. Following the completion of the transaction, the senior vice president owned 172,129 shares of the company's stock, valued at approximately $7,403,268.29. This trade represents a 11.95% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 97,790 shares of company stock valued at $3,634,659. Insiders own 7.60% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. LADENBURG THALM/SH SH lowered shares of Artivion from a "buy" rating to a "neutral" rating and boosted their price objective for the stock from $32.00 to $38.80 in a research note on Wednesday, August 13th. Canaccord Genuity Group boosted their price objective on shares of Artivion from $35.00 to $41.00 and gave the stock a "buy" rating in a research note on Friday, August 8th. Oppenheimer restated an "outperform" rating on shares of Artivion in a research note on Friday, August 8th. JMP Securities boosted their price objective on shares of Artivion from $33.00 to $42.00 and gave the stock a "market outperform" rating in a research note on Friday, August 8th. Finally, Wall Street Zen upgraded shares of Artivion from a "hold" rating to a "buy" rating in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $40.63.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.